Holen Sie sich die Stockscreener-App
39.07
2.57%
0.98
Handel nachbörslich:
41.06
1.99
+5.09%
Schlusskurs vom Vortag:
$38.09
Offen:
$37.85
24-Stunden-Volumen:
1.44M
Relative Volume:
0.95
Marktkapitalisierung:
$2.10B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.99M
KGV:
-13.04
EPS:
-2.9966
Netto-Cashflow:
$-24.94M
1W Leistung:
-0.74%
1M Leistung:
-9.48%
6M Leistung:
-42.27%
1J Leistung:
-13.16%
1-Tages-Spanne:
$37.85
$39.07
1-Wochen-Bereich:
$32.63
$41.62
52-Wochen-Spanne:
$32.63
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Firmenname
Soleno Therapeutics Inc
Sektor
Branche
Telefon
650-213-8444
Adresse
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
39.07 | 2.05B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-10-07 | Eingeleitet | Goldman | Buy |
| 2025-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-23 | Eingeleitet | TD Cowen | Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2024-12-02 | Bestätigt | Robert W. Baird | Outperform |
| 2024-12-02 | Bestätigt | Stifel | Buy |
| 2024-09-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-23 | Eingeleitet | Stifel | Buy |
| 2023-11-21 | Fortgesetzt | Guggenheim | Buy |
| 2020-09-29 | Eingeleitet | Guggenheim | Buy |
| 2020-01-10 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Soleno Therapeutics Inc Aktie (SLNO) Neueste Nachrichten
Soleno Therapeutics (NASDAQ:SLNO) Given New $85.00 Price Target at TD Cowen - MarketBeat
Soleno Therapeutics stock hits 52-week low at 37.95 USD - Investing.com Nigeria
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 1-Year LowShould You Sell? - MarketBeat
Soleno Therapeutics Names New Chief Financial Officer - marketscreener.com
Soleno Therapeutics stock hits 52-week low at 36.01 USD - Investing.com
Eli Lilly (LLY) Veteran Joins Soleno Therapeutics as CFO - GuruFocus
Soleno Therapeutics names Jennifer Fulk as CFO - Investing.com
Soleno Therapeutics Appoints Jennifer Fulk As Chief Financial Officer - Nasdaq
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer - The Manila Times
Eli Lilly veteran Jennifer Fulk to lead finances at rare disease firm Soleno - Stock Titan
Soleno Therapeutics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Soleno Therapeutics Announces New Chief Financial Officer Appointment - TipRanks
Biopharmaceutical company Soleno Therapeutics recently announced a major personnel appointment - Bitget
Soleno Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations By Investing.com - Investing.com Australia
SLNO: VYKAT XR achieved rapid adoption, strong revenue, and profitability in its first year post-launch - TradingView
Soleno (SLNO) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Soleno Therapeutics Q4 2025 earnings beat expectations - Investing.com
Soleno Therapeutics (NASDAQ:SLNO) Announces Earnings Results - MarketBeat
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q4 Revenue $91.7M, vs. FactSet Est of $88.8M - marketscreener.com
Soleno Therapeutics Earnings Review: Q4 Summary - Benzinga
BRIEF-Soleno Therapeutics Q4 EPS USD 0.8 - TradingView
Soleno Therapeutics Reports Fourth Quarter and Full-Year - GlobeNewswire
Soleno Therapeutics faces earnings test as launch metrics scrutinized By Investing.com - Investing.com UK
Soleno Therapeutics faces earnings test as launch metrics scrutinized - Investing.com
Soleno Therapeutics to Announce Q4 Earnings on February 25 - Intellectia AI
What to Expect from Soleno Therapeutics's Earnings - Benzinga
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Biotech Contender with 184% Upside Potential - DirectorsTalk Interviews
Will Soleno Therapeutics Inc. benefit from sector rotationEarnings Recap Summary & Weekly High Potential Stock Alerts - mfd.ru
Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc - GuruFocus
CenterBook Partners LP Acquires 38,282 Shares of Soleno Therapeutics, Inc. $SLNO - MarketBeat
Skandinaviska Enskilda Banken AB publ Increases Stock Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month LowHere's Why - MarketBeat
Soleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Readystate Asset Management LP Has $13.91 Million Holdings in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Commit To Purchase Soleno Therapeutics At $25, Earn 17.8% Annualized Using Options - Nasdaq
Wellington Management Group LLP Increases Stake in Soleno Therap - GuruFocus
Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance - Finviz
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Biotech Firm Surges with 200% Upside Potential - DirectorsTalk Interviews
(SLNO) Risk Channels and Responsive Allocation - Stock Traders Daily
TimesSquare Capital Management LLC Has $25.52 Million Stake in Soleno Therapeutics, Inc. $SLNO - MarketBeat
Soleno Therapeutics Updates PWS Launch, Reimbursement Trends and EU Review at Guggenheim Summit - MarketBeat
Soleno Therapeutics stock hits 52-week low at 37.95 USD By Investing.com - Investing.com Australia
Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year LowTime to Sell? - MarketBeat
Is Soleno Therapeutics Inc. currently under institutional pressure2025 Key Lessons & Intraday High Probability Alerts - mfd.ru
SLNO: Strong market uptake, stable safety, and robust reimbursement support ongoing growth - TradingView
Why is Soleno Therapeutics Inc. stock going downGap Up & Safe Entry Trade Reports - mfd.ru
Why Soleno Therapeutics Inc. (6XC) stock is listed among top recommendationsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - mfd.ru
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET - The Manila Times
Soleno Therapeutics to Report Fourth Quarter and Full-Year - GlobeNewswire
Finanzdaten der Soleno Therapeutics Inc-Aktie (SLNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Soleno Therapeutics Inc-Aktie (SLNO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hirano Patricia C | SEE REMARKS |
Jul 01 '25 |
Sale |
82.76 |
3,830 |
316,971 |
13,206 |
1.18%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):